Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Nanopore Technologies Regulatory News (ONT)

Share Price Information for Oxford Nanopore Technologies (ONT)

Share Price is delayed by 15 minutes
Get Live Data
114.60    -3.20 (-2.72%)
Bid:
116.10
Ask:
116.70
Spread: 0.60 (0.517%)
Market Cap: £1.11b
ONT Live PriceLast checked at - London Stock Exchange

Intraday Oxford Nanopore Technologies Share Chart

Block Admission Application

26 Mar 2026 15:00

RNS Number : 3093Y
Oxford Nanopore Technologies plc
26 March 2026
 

26 March 2026

Oxford Nanopore Technologies plc (the "Company")

Block Admission Application

The Company confirms that a new block admission application (the "New Block Admission Application") has been made to the London Stock Exchange for 50,000,000 ordinary shares of £0.0001 each in the capital of the Company (the "New Ordinary Shares") to be admitted to trading on the London Stock Exchange's main market for listed securities.

The New Ordinary Shares will, upon issue, rank equally with all other ordinary shares of £0.0001 each in the capital of the Company ("Ordinary Shares") that are then in issue.

The New Ordinary Shares will be issued by the Company from time to time under the terms of the following remuneration plans:

- the Oxford Nanopore Technologies Limited Share Option Scheme;

- the Oxford Nanopore Technologies Limited Share Option Plan 2018;

- the Oxford Nanopore Technologies Limited Long-Term Incentive Plan 2021;

- the Oxford Nanopore Technologies plc Long-Term Incentive Plan 2021;

- the Oxford Nanopore Technologies plc Deferred Bonus Plan 2021;

- the Oxford Nanopore Technologies plc Share Incentive Plan 2021; and

- the Oxford Nanopore Technologies plc Employee Stock Purchase Plan 2021.

The New Block Admission Application is in addition to the Company's existing block admission of 40,000,000 Ordinary Shares announced on 5 October 2021 (the "Existing Block Admission"). Currently, 5,160,512 Ordinary Shares remain subject to its Existing Block Admission.

It is expected that admission of the New Ordinary Shares will become effective on 30 March 2026.

Enquiries:

Investors

ir@nanoporetech.com 

Media 

media@nanoporetech.com

OxfordNanoporeTechnologies@teneo.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCZZGZFZVFGVZM
Date   Source Headline
28th Mar 20245:55 pmRNSHolding(s) in Company
12th Mar 20244:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
12th Mar 20247:00 amRNSOxford Nanopore to Present at Barclays Conference
8th Mar 202412:00 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirector/PDMR Shareholding
6th Mar 20247:00 amRNSFY23 Preliminary Results
1st Mar 20242:00 pmRNSIssue of Equity and Total Voting Rights
29th Feb 20246:00 pmRNSDirectorate Change
13th Feb 20244:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
2nd Feb 20244:30 pmRNSHolding(s) in Company
1st Feb 202412:00 pmRNSIssue of Equity and Total Voting Rights
22nd Jan 20247:00 amRNSExpansion of leadership team
11th Jan 20245:30 pmRNSEmployee Stock Purchase Plan - PDMR Notification
11th Jan 20245:30 pmRNSShare Incentive Plan - Director/PDMR Shareholding
9th Jan 20247:00 amRNSFY23 trading update
3rd Jan 20247:00 amRNSPresentation at 42nd Annual J.P. Morgan Conference
19th Dec 20232:00 pmRNSAppointment of Two Non-Executive Directors
12th Dec 20235:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
7th Dec 20234:30 pmRNSNanopore Community Meeting Technology Update
1st Dec 20235:00 pmRNSIssue of Equity and Total Voting Rights
30th Nov 20237:00 amRNSNational Australian rare disease programme
13th Nov 20235:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
13th Nov 202312:00 pmRNSParticipation in upcoming investor conferences
7th Nov 20238:30 amRNSAdmission to Trading on the London Stock Exchange
6th Nov 20237:00 amRNSIssue of Equity
1st Nov 20234:00 pmRNSIssue of Equity and Total Voting Rights
31st Oct 20237:00 amRNSApple showcases Oxford Nanopore in M3 launch
26th Oct 20236:10 pmRNSHolding(s) in Company
24th Oct 202312:30 pmRNSHolding(s) in Company
23rd Oct 20238:30 amRNSAdmission to Trading on the London Stock Exchange
23rd Oct 20238:30 amRNSIssue of Equity and Total Voting Rights
19th Oct 20237:00 amRNSCapital Markets Day - ONT expands into clinical
19th Oct 20237:00 amRNSbioMérieux makes investment in Oxford Nanopore
19th Oct 20237:00 amRNSMayo Clinic and Oxford Nanopore collaboration
11th Oct 20233:30 pmRNSShare Incentive Plan - Director/PDMR Shareholding
6th Oct 20233:00 pmRNSBlock Listing Interim Review
2nd Oct 20234:00 pmRNSIssue of Equity and Total Voting Rights
27th Sep 20235:00 pmRNSDirector Declaration
12th Sep 20233:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
12th Sep 20237:00 amRNSPresentation at the Morgan Stanley Conference
6th Sep 20237:00 amRNSInterim results for the 6 months ended 30 June 23
1st Sep 20233:00 pmRNSIssue of Equity and Total Voting Rights
25th Aug 202312:00 pmRNSNotice of Results and Capital Markets Day
11th Aug 20235:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
1st Aug 20235:30 pmRNSIssue of Equity and Total Voting Rights
17th Jul 20237:00 amRNSHalf Year Trading Update
13th Jul 20233:30 pmRNSKate Priestman appointed as Non-Executive Director
11th Jul 20235:30 pmRNSShare Incentive Plan - Director/PDMR Shareholding
3rd Jul 20233:30 pmRNSIssue of Equity and Total Voting Rights
13th Jun 20234:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.